pharma news, views and analysis

in Spotlight

Spotlight on: The Future of Medical Affairs
August 17, 2017 Share
X
Spotlight on: The Future of Medical Affairs
https://pharmaphorum.com/views-and-analysis/spotlight-future-medical-affairs/
in Views and analysis

Spotlight on – The Future of Oncology Clinical Trials
September 28, 2016 Share
X
Spotlight on – The Future of Oncology Clinical Trials
https://pharmaphorum.com/views-and-analysis/future-oncology-focus/
in News

NICE fires shots at pharma over legal battle
September 25, 2017 Share
X
NICE fires shots at pharma over legal battle
https://pharmaphorum.com/news/nice-fires-shots-pharma-ahead-legal-battle/
in News

NICE recommends Bayer drug for severe short-sightedness
September 25, 2017 Share
X
NICE recommends Bayer drug for severe short-sightedness
https://pharmaphorum.com/news/nice-recommends-bayer-myopic-chorodial-neovascularisation/
in Views and analysis

Neurotechnology for tailored patient care
September 25, 2017 Share
X
Neurotechnology for tailored patient care
https://pharmaphorum.com/views-and-analysis/neurotechnology-patient-care/
in Views and analysis

Progress in mental health digital innovation
September 22, 2017 Share
X
Progress in mental health digital innovation
https://pharmaphorum.com/views-and-analysis/mental-health-digital-innovation/

FDA rejects J&J’s sirukumab RA drug

September 25, 2017

The FDA has rejected Johnson & Johnson’s next-generation rheumatoid arthritis drug, sirukumab, calling for more clinical data to

FDA rejects J&J’s sirukumab RA drug

https://pharmaphorum.com/news/fda-rejects-jjs-sirukumab-ra-drug/

Novartis’ CAR-T drug needs new payment model, says Express Scripts

September 25, 2017

Cost of Novartis’ revolutionary therapy is obstacle, says CMO.

Novartis’ CAR-T drug needs new payment model, says Express Scripts

https://pharmaphorum.com/news/novartis-car-t-expensive-us-health-system-express-scripts/

Fitbit shares continue to drop as Ionic receives lacklustre reviews

September 22, 2017

Mediocre Ionic smartwatch reviews cause almost 8% drop in Fitbit shares.

Fitbit shares continue to drop as Ionic receives lacklustre reviews

https://pharmaphorum.com/news/fitbit-shares-drop-ionic/

See all

Interview: AZ’s immunotherapy gamble starts to pay off

September 22, 2017

Robert Iannone, AstraZeneca’s head of immune-oncology research, on the unpredictable immunotherapy market.

Interview: AZ’s immunotherapy gamble starts to pay off

https://pharmaphorum.com/views-and-analysis/az-immunotherapy-gamble-pays-off/

Pharma 2022: big pharma will remain a constant

September 20, 2017

Pharma 2022: big pharma to maintain its position, ready to pounce on any newcomer that shows promise.

Pharma 2022: big pharma will remain a constant

https://pharmaphorum.com/views-and-analysis/pharma-2022-big-pharma-remains-constant/

What is ‘affordable’? The reality of the PPRS

September 19, 2017

PPRS impact: has it kept the branded medicines bill within affordable limits?

What is ‘affordable’? The reality of the PPRS

https://pharmaphorum.com/views-and-analysis/pprs-impact-drug-budget/

See all

Neurotechnology for tailored patient care

September 25, 2017

Advanced implantable medical devices could treat hundreds of chronic conditions in the future.

Neurotechnology for tailored patient care

https://pharmaphorum.com/views-and-analysis/neurotechnology-patient-care/

Pharma 2022: big pharma will remain a constant

September 20, 2017

Pharma 2022: big pharma to maintain its position, ready to pounce on any newcomer that shows promise.

Pharma 2022: big pharma will remain a constant

https://pharmaphorum.com/views-and-analysis/pharma-2022-big-pharma-remains-constant/

Get real: virtual reality for healthcare comes of age

September 15, 2017

After a few false dawns over the years, has virtual reality’s time come?

Get real: virtual reality for healthcare comes of age

https://pharmaphorum.com/views-and-analysis/get-real-virtual-reality-healthcare-comes-age/

See all

Can pharma ever be a genuine partner to the NHS?

August 29, 2017

Can pharma ever be a genuine partner to the NHS?

https://pharmaphorum.com/webinars/live-webinar/can-pharma-ever-genuine-partner-nhs/

19/09/2017

Pharma’s digital landscape: the evolution of multichannel strategy

August 21, 2017

Pharma’s digital landscape: the evolution of multichannel strategy

https://pharmaphorum.com/webinars/live-webinar/pharmas-digital-landscape-evolution-multichannel-strategy/

06/09/2017

Pharma and proactive, preventative healthcare: how to use the pharmacy channel

August 2, 2017

Pharma and proactive, preventative healthcare: how to use the pharmacy channel

https://pharmaphorum.com/webinars/webinars-on-demand/pharma-proactive-preventative-healthcare-use-pharmacy-channel/

See all

Seizing the potential of commercial outsourcing in the pharmaceutical sector

February 23, 2017

The power and potential of outsourcing has long been recognised as a core enabler of business growth. Yet

Seizing the potential of commercial outsourcing in the pharmaceutical sector

https://pharmaphorum.com/whitepapers/seizing-potential-commercial-outsourcing-pharmaceutical-sector/

Pricing and market access – facts versus fiction

January 31, 2017

‘Pricing and Market Access Outlook: 2017 Edition’ includes fresh analysis from QuintilesIMS of market forces and pricing policy based on facts and figures behind approvals of new molecular entities in 2015.

Pricing and market access – facts versus fiction

https://pharmaphorum.com/white-papers/pricing-market-access-facts-versus-fiction/

Healthcare in the Digital Age

November 22, 2016

A new whitepaper presenting analysis of exclusive M3 (EU) data, revealing the digital and technological habits and preferences of doctors and how pharma can best engage.

Healthcare in the Digital Age

https://pharmaphorum.com/whitepapers/healthcare-digital-age/

See all